- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study2020 | 1. lékařská fakulta
- Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study2021 | Publikace bez příslušnosti k fakultě
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | Lékařská fakulta v Hradci Králové, 1. lékařská fakulta, Ústřední knihovna
- Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population2019 | Publikace bez příslušnosti k fakultě
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial2023 | 1. lékařská fakulta
- Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study2023 | Lékařská fakulta v Hradci Králové, 1. lékařská fakulta
- Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial2021 | 1. lékařská fakulta
- A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)2017 | Lékařská fakulta v Hradci Králové
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk2020 | 1. lékařská fakulta
- Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes2022 | 1. lékařská fakulta
- Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data2022 | Lékařská fakulta v Hradci Králové, 1. lékařská fakulta, 3. lékařská fakulta, Ústřední knihovna, Lékařská fakulta v Plzni
- Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice2021 | Lékařská fakulta v Hradci Králové, 1. lékařská fakulta, 3. lékařská fakulta
- Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis2021 | Lékařská fakulta v Hradci Králové
- Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy2022 | Lékařská fakulta v Hradci Králové, 1. lékařská fakulta, 3. lékařská fakulta
- Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma2022 | 1. lékařská fakulta